News

Merck CEO addresses RFK Jr.'s removal of all members of CDC's vaccine advisory committee
CNBC's Angelica Peebles reports on news regarding vaccines.
Fierce Biotech1d
Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
STAT15h
Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more
Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...
Merck: Best Case For Option Collars We'll Ever See
Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...
Merck Stock’s Ticking Keytruda Time Bomb
However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...
Merck's potential blockbuster cholesterol pill succeeds in late-stage studies
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
Explore more
BioPharma Dive1d
Merck claims study success with PCSK9 cholesterol pill
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
Fierce Pharma1d
Feeling RSV heat from Merck, Sanofi lays out early supply plans for Beyfortus
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
Zacks.com on MSN7h
Merck (MRK) Rises Higher Than Market: Key Facts
The most recent trading session ended with Merck (MRK) standing at $81.35, reflecting a +2.55% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily gain of 0.55%.